February 18, 2026 03:21 am (IST)

Make this your homepage

All Finance

Actor Rajpal Yadav granted interim bail in ₹9-crore cheque bounce case | Learn AI or become redundant: Microsoft India President issues stark message | India’s wholesale inflation rises to 1.81% in January as manufacturing prices surge | 'India at forefront of AI revolution': PM Modi welcomes world leaders to Delhi summit | Rs 5,000 to women ahead of Tamil Nadu polls! Vijay slams Stalin, says: ‘take the money, blow the whistle’ | Modi congratulates Tarique Rahman as BNP clinches majority in Bangladesh polls | Bangladesh Polls: Tarique Rahman-led BNP secures 'absolute majority' with 151 seats in historic comeback | BJP MP files notice to cancel Rahul Gandhi's Lok Sabha membership, seeks life-long ban | Arrested in the morning, out by evening: Tycoon’s son walks free in Lamborghini crash case | ‘Why should you denigrate a section of society?’: Supreme Court pulls up ‘Ghooskhor Pandat’ makers

Strides Arcolab signs agreement with Gilead Sciences

India Blooms News Service | | Jan 21, 2015, at 02:38 am

#Strides Arcolab signs agreement with Gilead Sciences

Bangalore/Kolkata, Jan 20 (IBNS): Strides Arcolab Limited (Strides) on Tuesday announced that it has entered into a licensing agreement with Gilead Sciences, Inc. under which Gilead has extended non-exclusive rights to Strides to manufacture and distribute Tenofovir Alafenamide (TAF), both as a single agent product and in combination with other drugs.

The license being granted to Strides extends to 112 countries, which together account for more than 30 million people living with HIV.

As part of the licensing agreement, pending U.S. Food and Drug Administration (US FDA) approval of the Gilead product, Strides will receive a technology transfer from Gilead, enabling Strides to manufacture low-cost versions of TAF for developing countries.

TAF is a novel nucleotide reverse transcriptase inhibitor that has demonstrated high antiviral efficacy at a dose 10 times lower than Gilead’s Viread (tenofovir disoproxil fumarate), as well as an improved renal and bone safety profile.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.

India
International

Related Images

Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:41 pm

Veedol signs former Indian skipper Sourav Ganguly as brand ambassador Jun 29, 2024, at 06:38 am

In Images: Glimpses from Bengali film Fatafati's premiere May 13, 2023, at 08:39 pm